Studies have shown that inhibiting HO-1 significantly enhances the effects of gemcitabine and radiotherapy, emphasizing that HO-1 inhibition can serve as a potential strategy to improve pancreatic cancer treatment outcomes and provide new ideas for clinical practice [45], suggesting their utility as adjuvant agents in BU-based regimens. Here, HMOX1 is linked to familial pancreatic carcinoma.